Results 131 to 140 of about 98,309 (302)

A CCL5+CD20+CD8+ T cell subset drives pathogenic transformation of synoviocytes in rheumatoid arthritis via JAK-STAT signaling

open access: yesCell & Bioscience
Background In rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) acquire an aggressive phenotype promoting inflammation and joint damage. While FLS interactions with recruited T cells are established, drivers of FLS aggressiveness and the role
Haonan Jia   +12 more
doaj   +1 more source

MUC1 as a Survival Effector of Radiotherapy‐Induced Epithelial Hybrid States in Basal‐Like Breast Cancer

open access: yesInternational Journal of Cancer, EarlyView.
Basal‐like breast cancer (BLBC) is aggressive and often exhibits inherent or acquired resistance to radiotherapy (RT), a primary treatment option. RT resistance is underpinned by molecular alterations, many of which are poorly understood. Here, RT‐induced transcriptomic changes were analyzed using bulk and spatial sequencing in a BLBC mouse model and ...
Garyfallia Pantelaiou‐Prokaki   +12 more
wiley   +1 more source

Assessment of CD20 Marker as a Prognostic Predictor for Patients with Classical Hodgkin Lymphoma

open access: yes
Eman Atarji,1,2 Yara M Daous,2,3 Ahmed Barefah,2,4 Hatem Alahwal,2,4 Bushra Albaity,2,4 Nora Y Hakami,1 Heba Alkhatabi,1,2,5 Talal Qadah1,2,5 1Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University ...
Albaity B   +7 more
core  

The Growth Supporting Role of ZDHHC11 Is Linked to the MEF2B–BCL6 Regulatory Circuit in Burkitt Lymphoma

open access: yesInternational Journal of Cancer, EarlyView.
MEF2B and BCL6 have established functions in germinal center B‐cell biology and lymphomagenesis. The mechanism of MEF2B deregulation and its significance for cell survival in Burkitt lymphoma however remain unclear. This study highlights MEF2B as a crucial transcription factor in Burkitt lymphoma and suggests ZDHHC11 as an upstream regulator of MEF2B ...
Lotteke J. Y. M. Ziel‐Swier   +12 more
wiley   +1 more source

CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia

open access: yesJournal of Translational Medicine
Background Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising advancement in CAR cell therapy, addressing limitations observed in CAR-T cell therapy.
Na Yang   +11 more
doaj   +1 more source

Scoring of CD20 positive cells.

open access: yes, 2016
Scoring of CD20 positive cells.
Tom H. M. Ottenhoff (160303)   +9 more
core   +1 more source

Gene expression signatures from single‐cell transcriptomics predict Sjögren's syndrome

open access: yesiMetaOmics, EarlyView.
A machine learning‐based 12‐gene signature (SjS.Sig) was developed from scRNA‐seq data of PBMCs from Sjögren's syndrome patients. The model was validated using bulk RNA‐seq datasets and further confirmed through flow cytometry and qPCR analysis in an independent clinical cohort, demonstrating robust diagnostic potential.
Shumin Cheng   +20 more
wiley   +1 more source

Lineage Determination of CD20– B-Cell Neoplasms

open access: yes, 2006
We studied 61 CD20- B-cell lymphomas, including 29 cases of precursor B-cell lymphoblastic leukemia/lymphoblastic lymphoma (B-ALL/B-LBL), 25 cases of CD20- recurrent mature B-cell lymphoma after rituximab therapy, and 7 cases of CD20- diffuse large B ...
Lawrence M. Weiss   +7 more
core   +1 more source

Nanopore direct RNA sequencing and the epitranscriptome: Advances in mapping native RNA landscapes

open access: yesiMeta, EarlyView.
Nanopore direct RNA sequencing advances transcriptomics by capturing full‐length transcripts and multiple RNA modifications; this review details its principles, workflows, tools, applications, challenges, and future research potential. Abstract Nanopore direct RNA sequencing (DRS) has transformed transcriptomics by enabling single‐molecule, long‐read ...
Tianyuan Zhang   +27 more
wiley   +1 more source

Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma

open access: yes, 2007
We report the first case of diffuse large B-cell lymphoma (DLBCL) of the stomach displaying CD20-negative relapse after rituximab-containing treatment and the re-appearance of CD20 expression at the second failure.
C. Doglioni   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy